Neoplasms

Symptoms and General Pathology

All Conditions

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Neoplasm Metastasis

Prostatic Neoplasms

Recurrence

Genital Neoplasms, Male

Urogenital Neoplasms

Genital Diseases

Genital Diseases, Male

Urogenital Diseases

Prostatic Diseases

Male Urogenital Diseases

Antineoplastic Agents

All Drugs and Chemicals

Docetaxel

Fluorodeoxyglucose F18

Androgen Antagonists

Androgens

Tubulin Modulators

Antimitotic Agents

Hormones

Hormone Antagonists

antiandrogen therapy

docetaxel

C-11 acetate PET scan

F-18 FDG PET scan

Tc-99m bone scan

CT scan of the chest, abdomen and pelvis

Evan Y. Yu, MD

RATIONALE: Imaging procedures, such as PET scan, may help doctors predict a patient's response to treatment and help plan the best treatment.

PURPOSE: This clinical trial is studying carbon-11 acetate and fludeoxyglucose F 18 PET scan of the bone in patients with metastatic prostate cancer that has spread to the bone.

OBJECTIVES:

Primary

* Correlate pre-treatment and 3-month post-treatment carbon-11 (\^11C) acetate and fludeoxyglucose F 18 positron emission tomography (\^18F-FDG PET) images with changes in clinical response measures in patients with bone-dominant metastatic prostate cancer.

Secondary

* Compare \^11C acetate and \^18F-FDG PET scanning results with bone scintigraphy in these patients to determine which best predicts clinical response.
* Correlate changes in \^11C acetate and \^18F-FDG PET with changes in prostate-specific antigen level.
* Correlate changes in \^11C acetate and \^18F-FDG PET with clinical symptom parameters (pain scale scores and analgesic usage scales).
* Correlate \^11C acetate and \^18F-FDG PET scan response with clinical time to progression.
* Determine if PET scan response can predict duration of progression-free survival.

OUTLINE: This is a pilot study. Patients are stratified according to hormone response (sensitive \[stratum 1\] vs refractory \[stratum 2\]).

Patients undergo carbon-11 acetate and fludeoxyglucose F 18 positron emission tomography imaging prior to and 3 months after initiation of either androgen-deprivation therapy (stratum 1) or docetaxel (stratum 2).

Pain and quality of life are assessed at baseline and at 3 months.

Patients are followed every 3 months for up to 5 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone

Positron Emission Tomography Imaging of Bone in Patients With Metastatic Prostate Cancer - A Pilot Study Evaluating Treatment Response

National Cancer Institute (NCI)

University of Washington

Principal Investigator

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone	NCT00392938	Metastatic Canc... Prostate Cancer	antiandrogen th... docetaxel C-11 acetate PE... F-18 FDG PET sc... Tc-99m bone sca... CT scan of the ...	18 Years - 120 Years	University of Washington
Carbon-11 Acetate and Fludeoxyglucose F 18 PET Scan of the Bone in Patients With Metastatic Prostate Cancer That Has Spread to the Bone	NCT00392938	Metastatic Canc... Prostate Cancer	antiandrogen th... docetaxel C-11 acetate PE... F-18 FDG PET sc... Tc-99m bone sca... CT scan of the ...	18 Years - 120 Years	University of Washington

Spots Global Cancer Trial Database for ct scan of the chest, abdomen and pelvis